There is increasing evidence suggesting that both angiogenesis and endothelial injury are involved in GVHD. To study the dynamics of angiogenesis, we examined 26 patients with AML who had undergone allogeneic haematopoietic SCT. All were in CR and had either acute GVHD (aGVHD) or chronic GVHD (cGVHD). We performed immunohistochemical studies of BM microvessel density (MVD) using Abs against vascular-endothelial (VE)-cadherin, CD34 and CD105, and expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 and VEGFR-2. At the time of diagnosis, the MVD in AML patients was higher than that in the normal controls, and the MVD decreased after induction chemotherapy. Patients with aGVHD had a significantly higher MVD than patients without aGVHD. Conversely, patients with cGVHD did not have a significantly different MVD. In previous aGVHD, we also found more VEGF þ megakaryocytes. XY FISH in sex-mismatched patients showed that the BM blood vessels consisted mainly of recipient endothelial cells. Taken together, these results suggest that new vessel formation and the VEGF/VEGFR system are involved in aGVHD.
INTRODUCTION
Allogeneic haematopoietic SCT (allo-HSCT) is a curative approach for patients with haematological malignancies. 1 The success rate of HSCT is severely limited by acute GVHD (aGVHD), which is mediated by host-reactive, donor-derived T cells. The primary target organs of these T cells in GVHD are epithelial cells in the skin, liver and intestine. 2 There is increasing evidence for the involvement of endothelial cells in GVHD. 3 Early endothelial injury syndromes, such as transplant-associated microangiopathy, venoocclusive disease of the liver, diffuse alveolar haemorrhage, engraftment syndrome and capillary leak syndrome, all share features with aGVHD. [3] [4] [5] New blood vessel formation (angiogenesis) is fundamental to tumour growth and metastasis. 6 Vascular endothelial growth factor (VEGF) has a key rate-limiting role in promoting tumour angiogenesis and exerts its effects by binding to its tyrosine kinase receptors: VEGF receptor-1 (VEGFR-1) and VEGFR-2. 7, 8 Several studies have suggested that angiogenesis plays an important role not only in solid tumours but also in haematolymphoid malignancies. [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, angiogenesis seems to be involved in GVHD. 17, 18 To the best of our knowledge, until now, no study has examined the correlation of GVHD with angiogenesis and VEGF expression in the BM after allo-HSCT. The aim of our study was to examine BM microvessel density (MVD) dynamically from initial diagnosis of AML through the point of allo-HSCT, and 1, 3, 12, 24 and 60 months after allo-HSCT, The correlation of these results with the presence and degree of either acute GVHD or chronic GVHD (cGVHD) was assessed and compared with normal controls. In sex-mismatched transplantations, we examined the source of endothelial cells by using XY FISH probes to assess endothelial cell chimaerism. CD34, CD105 and vascular-endothelial (VE)-cadherin were used as angiogenic markers. CD105 is a component of the transforming growth factor-b receptor complex, 19 and is preferentially expressed in newly formed vessels, thus being a marker of proangiogenic activity. [19] [20] [21] VE-cadherin is an endothelial-specific adhesion molecule located at the junctions between endothelial cells. 22 In the present study, we focused on VE-cadherin for vessel staining because, in a previous study, Penack et al. 17 reported that the anti-VE-cadherin Ab E4G10 inhibited neovascularisation by donor BMderived cells without affecting host vascularisation, as well as inhibited both GVHD and tumour growth, and increased survival in a murine allo-HSCT model, suggesting that VE-cadherin is a potential therapeutic target.
PATIENTS AND METHODS Patients
The study was performed according to the regulations of the local ethics committee. Patients included had AML, underwent an allo-HSCT at our institution between 2004 and 2010 and fulfilled the following criteria: (1) aGVHD and/or/ cGVHD diagnosed and graded by standard criteria, controls having had neither (2) trephine BM biopsies available at diagnosis, before allo-HSCT, and at 1, 3, 12, 24, and 60 months after allo-HSCT (less or equal to two missing biopsies were acceptable); and (3) AML in CR at the time of the BM biopsies. AML was diagnosed according to the World Health Organisation (WHO) criteria. 23 Remission status was defined according to the International Working Group for Diagnosis, Standardisation of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in AML. 24 Both aGVHD and cGVHD were diagnosed based on clinical symptoms and/or skin, oral mucosa, liver or gut biopsies and were graded using the standard National Institute of Health consensus criteria. 25 The GVHD prophylaxis administered was CsA and MTX. aGVHD of less than grade II was treated with steroids (2 mg/kg/day). Chimaerism analysis in the whole blood was carried out at each protocol follow-up examination after allo-HSCT using a STR analysis method (AmpFlSTR Profiler, Applied Biosystems, Foster City, CA, USA). A total of 26 patients with AML were included. Clinical and follow-up data were obtained by reviewing the charts. The age-matched controls (median age 51 years, range 24-70) for immunohistochemical studies included 20 nontransplanted patients without evidence of BM abnormalities and with normal blood counts. Biopsies were performed to rule out any haematological abnormalities.
Immunohistochemistry
All of the specimens were formalin fixed. The samples were immunohistochemically stained for CD34 (Ventana ready to use kit; prediluted; Ag retrieval CC1 short) using an automated immunostainer (Benchmark, Ventana, Tucson, AZ, USA 12 This allowed all vessels (and not only hot spots) to be taken into consideration. In the first step of our study, we analysed the MVD 12 months after allo-HSCT with all three Abs (CD34, CD105 and VE-cadherin) to determine whether there was a difference in expression in patients with GVHD. The optimal results were achieved with VE-cadherin; thus, the second step of the study used VE-cadherin for the time points from diagnosis to 60 months after allo-HSCT. The expression of VEGF and the VEGF receptors (VEGFR-1 and VEGFR-2) was assessed by counting the number of positively stained cells in three 0.283 mm 2 fields at Â 400 magnification, and then the mean for 1 mm 2 was calculated. The percentage of VEGF-positive megakaryocytes was also assessed.
FISH
FISH was performed in sex-mismatched patients (female donor/male recipient) on the BM biopsy specimen obtained 12 months after allo-HSCT, using the directly labelled, dual-colour (red/green) X-and Y-chromosome probe mix (Xp11.1-q11.1/Yq12) Z-2016 (ZytoVision, Bremerhaven, Germany). The sections were processed with a paraffin pretreatment reagent kit (Abbott/Vysis, Baar, Switzerland), and hybridisation was performed according to the manufacturer's specifications. Denaturation was conducted for 10 min at 73 1C, and the FISH probes were incubated overnight at 37 1C in Hybrite (Abott/Vysis). Counterstaining was performed with 4,6-diamidino-2-phenylindole. The FISH signals were visualised on a Zeiss fluorescence microscope equipped with double bandpass filters for simultaneous visualisation of green and orange signals. Analysis of 100 endothelial cells and 2000 haematopoietic cells was performed.
Statistical analysis
Statistical analyses, including a distribution analysis and descriptive statistics, were performed with IBM SPSS Statistics 19.0, Chicago, IL, USA. Comparisons were performed using the Kruskal-Wallis and Mann-Whitney U-tests. Spearman's rank correlation coefficient and R 2 were applied where appropriate. Differences were considered statistically significant at Po0.05; two-sided tests were used throughout the analysis.
RESULTS

Patients' baseline clinical and histological characteristics
Of the 26 patients (median age 47 years, range 24-66) included in the study, 14 were male and 12 were female. The distribution of cases according to the WHO classification is presented in Table 1 . All of the patients had a myeloablative conditioning regimen (irradiation-based therapy in 16 patients and chemotherapy alone in 10), and they all received PBSCs as a stem cell source. The donors were matched sibling donors (n ¼ 18), matched unrelated donors (n ¼ 7) or a mismatched haploidentical donor from the patient's family (n ¼ 1). Chimaerism analysis at the protocol examination time points after allo-HSCT showed 100% donor alleles in all patients. The median time interval from allo-HSCT to aGVHD onset of any grade was 21 days (range 7-146 days). The aGVHD type was classic acute in 13 patients and late-onset acute in 2 patients. There were four groups of patients: (1) No GVHD (n ¼ 3); (2) only aGVHD (n ¼ 2); (3) only cGVHD (n ¼ 9); and (4) aGVHD and cGVHD (n ¼ 12). The aGVHD resolved in all patients after standard steroid therapy. All patients with cGVHD had ongoing disease.
Microvessel density MVD was assessed by immunostaining with Abs against CD34, CD105 and VE-cadherin 12 months after allo-HSCT and against VEcadherin alone at all of the other time points. Endothelial cells and scattered BM blasts stained positively for CD34 with a moderate to strong intensity. The staining pattern was uniformly cytoplasmic/ membraneous. In all cases studied, CD34 þ blasts were o1%. Microvessels stained positively for VE-cadherin and CD105, whereas larger vessels did not (Figures 1a-d) . The staining pattern for both CD105 and VE-cadherin was uniformly membranous.
At the time of AML diagnosis, the MVD-VE-cadherin levels were significantly higher than those of the controls (Table 2 and Figures  1a and b and 2 ). After induction chemotherapy and before allo-HSCT, the MVD-VE-cadherin levels decreased to the levels of the normal controls. In patients with aGVHD, the MVD-VE-cadherin levels increased, whereas they remained at the level of controls in patients without GVHD. The MVD-VE-cadherin differences between patients with aGVHD and those without aGVHD were significant until 24 months post transplant ( Table 2 ). The aGVHD resolved in all patients after therapy, and the MVD-VE-cadherin levels decreased but did not reach the levels measured directly before allo-HSCT (Figure 2 ). In patients with cGVHD, we found no significant changes in the MVD-VE-cadherin levels compared with 
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patients without cGVHD at the time points 43 months after allo-HSCT (Table 2) . However, the MVD was always higher in patients than in normal controls. At 12 months after allo-HSCT, the patients with previous aGVHD (aGVHD had resolved in all patients at the 12-month time point) had higher CD105-and VE-cadherin-MVD than patients without aGVHD (Table 3 ). The MVD in all patients after allo-HSCT was higher than in the controls. In patients with cGVHD, the CD34-MVD was slightly lower than that of patients without cGVHD but was still higher than that of controls ( Table 3 ). The subgroup analysis (GVHD grading) of patients without up to severe cGVHD showed no significant differences with increasing GVHD grade, which was probably because of small patient numbers in each group. The MVD, as assessed by VE-cadherin expression, correlated with the CD105-MVD (Spearman's r ¼ 0.860, P ¼ 0.005, R 2 ¼ 0.604). The changes in MVD over time are shown for each Figure 3 . The patients without GVHD (green lines) had a stable, low MVD, whereas patients who had only aGVHD had a higher MVD (blue lines), which did not return to normal levels. Patients with both aGVHD and cGVHD (red lines) had a higher than normal MVD until 2 years after allo-HSCT; in these patients, MVD declined after aGVHD had resolved but did not reach normal levels. Most patients who had only cGVHD had a stable, low MVD (purple lines).
VEGF and VEGF receptor expression VEGF staining was diffuse and cytoplasmic. Strong staining was observed in the megakaryocytes and interstitial BM histiocytes (Figure 1e ). The relative VEGF expression (mean % VEGF-positive megakaryocytes) was higher in patients 12 months after allo-HSCT than in the controls (76 ± 25% and 58 ± 27%, respectively, P ¼ 0.043; Mann-Whitney U-test). In patients with resolved aGVHD, the number of VEGF-positive megakaryocytes was higher than in patients who had not experienced any instances of aGVHD (Table 3) , as assessed by VE-cadherin expression, in patients with AML who underwent an allo-HSCT; plots show microvessel density from the time of diagnosis until 5 years after allo-HSCT. Green box-plots represent patients without aGVHD, and red box-plots represent patients with aGVHD. The dashed line represents the mean MVD-VEcadherin levels of normal controls. was found in either the vasculature of BM sections in patients and controls. In patients, the MVD assessed by CD105 and VE-cadherin correlated with the relative number of VEGF-positive cells at 12 months after allo-HSCT (Spearman's r ¼ 0.484, P ¼ 0.017, R 2 ¼ 0.125; and r ¼ 0.606, P ¼ 0.002, R 2 ¼ 0.506, respectively). In all AML samples and controls, the VEGFR-1 and VEGFR-2 staining was heterogeneous and of weak intensity. VEGFR-2 was expressed in megakaryocytes, mononuclear cells and isolated endothelial cells, whereas VEGFR-1 was not expressed in megakaryocytes, but in precursor cells.
FISH
Five male patients who were grafted from a female donor were screened for donor-derived endothelial and haematopoietic cells using FISH for X and Y chromosomes 12 months after allo-HSCT. This screening revealed a persistence of the recipient-type X-and Y-chromosome karyotype in most of the BM endothelial cells and in all osteocytes. Single donor-type endothelial cells with two X signals and no Y signal were rarely observed (3 of 5 patients), whereas nearly 100% of the nucleated marrow cells were of the donor type. In one patient, the endothelial cells in a microvessel had a higher number of donor-derived cells (B10% of the endothelial cells in one vessel; Figure 4 ).
DISCUSSION
The formation of new blood vessels appears to be involved in GVHD, 17 and endothelial cells appear to be a target of GVHD, resulting in endothelial injury. 3 We examined the role of angiogenesis, together with the pro-angiogenic factor VEGF and its receptors, in GVHD in patients with AML before and up to 5 years after allo-HSCT. At diagnosis, we found significantly increased MVD-VE-cadherin levels, which declined to normal levels after induction chemotherapy as described in previous studies. 26 We found increased MVD in aGVHD but not in cGVHD. Newly formed and established BM blood vessels after allo-HSCT consisted primarily of recipient cells.
In our study, VE-cadherin was expressed in microvessels, and the VE-cadherin-MVD levels correlated with CD105-MVD and with the number of VEGF-positive megakaryocytes. Pan-endothelial cell markers such as anti-CD34 Abs react not only with newly proliferating vessels but also with established vessels. 27, 28 Anti-CD105 Abs appear to be more specific for newly formed endothelial cells. 29, 30 VE-cadherin, the principal cell-cell junction molecule of endothelial cells, is required for normal vasculature development in the mouse embryo and for new vessel formation in the adult. 31 VE-cadherin is involved in vascular morphogenesis and endothelial survival. The fact that its expression is upregulated during vascular proliferation suggests that VE-cadherin may be a key player in this process, 32 as well as a relevant marker (as indicated by our observations) of angiogenesis. Recent studies have shown that tumour angiogenesis can be blocked by Abs against VE-cadherin, suggesting that VE-cadherin activity is necessary for vascular proliferation in adults. 33, 34 In our study, the MVD assessed by VE-cadherin best reflected BM neovascularisation differences between patients with aGVHD, patients without aGVHD and control subjects. MVD-VE-cadherin levels normalised after myeloablative therapy and remained stable (almost identical to those of controls) in patients without aGVHD; however, the levels increased shortly after allo-HSCT in those with aGVHD and remained elevated until aGVHD resolved. Together with the observations from murine models, 17 these dynamics suggest that VE-cadherin might be useful as a therapeutic target in patients with steroid-refractory aGVHD; such patients have a poor prognosis, and novel therapies are urgently needed. 35 Anti-angiogenic agents targeting the VEGF/ VEGFR-system such as bevacizumab (a humanised monoclonal anti-VEGF Ab), sunitinib and sorafenib are already approved for the treatment of solid tumours. 36 However, the use of angiogenesis inhibitors in GVHD depends on the relationship between angiogenesis, VEGF and GVHD, the underlying mechanisms of which are not yet understood. Increased angiogenesis and VEGF expression in GVHD could be the direct cause of GVHD or a response to GVHD development, and targeting angiogenesis makes sense only in the former scenario. Taking into account our present study, which suggests a role for angiogenesis specifically in aGVHD, further experimental studies are necessary to confirm the preclinical data and to examine the potential of targeting VEGF and other angiogenic pathways in such instances.
In addition, we observed that the relative proportion of VEGFpositive megakaryocytes was higher in patients with aGVHD than in patients without aGVHD or the control subjects and was correlated with MVD, especially with VE-cadherin-positive microvessels. This finding suggests that proangiogenic factors derived from the haematopoietic cells and megakaryocytes onsite might be involved in aGVHD. This is not surprising because megakaryocytes are the major source of VEGF in the BM niche 12 and in platelets. 37 There is much controversy on the role and dynamics of VEGF in GVHD, which might be explainable by the different post transplant time points of determination and different measurement assays. [38] [39] [40] In a recent study by Porkholm et al., 41 the levels of angiopoietin-2 and VEGF were measured in paediatric patients undergoing allo-HSCT. They showed that higher angiopoietin-2 levels predict higher nonrelapse mortality and, with coexisting high VEGF, also shorter EFS after HSCT, which is in line with our observed higher VEGF expression in aGVHD. In our study, VEGF expression in megakaryocytes was examined in situ 1 year after allo-HSCT, thus representing a more 'stable' phase than the period immediately after allo-HSCT. It should be noted that megakaryocytes represent a minor population (1-2% of all nucleated BM cells), and their VEGF mRNA content might not be detectable by integrative global gene expression analysis of unsorted BM cells. The pathogenesis of GVHD is still not completely understood. Conditioning regimens such as TBI result in initial toxic epithelial injury to organs such as the gut, liver and skin, thereby causing a cell-damage-induced proinflammatory cytokine milieu. 2 In a study of patients with cGVHD, there was an extensive loss of microvessels in the skin compared with healthy controls. 4 In our study, we found no significant differences in patients with cGVHD, with the exception of a slightly increased MVD-VE-cadherin levels at the onset of symptoms 1 year after allo-HSCT. In patients with resolved aGVHD but persisting cGVHD, we found a slightly decreasing MVD over the course of 60 months, whereas patients with aGVHD but not cGVHD had a continuously high MVD level. The decreasing MVD in patients with cGVHD could be because of a late vessel-vanishing effect.
It was recently suggested that donor-derived endothelial cells participate in endothelial repair during the effector phase of aGVHD, 42 and donor-derived endothelial cells were detected in 25% of the sex-mismatched skin biopsies immediately following allo-HSCT (especially in patients with aGVHD) and at later time points. 43 In our study, we found very few donor-derived endothelial cells in the BM, with the exception of one patient, whose microvessels had a higher number of donor-derived endothelial cells. This patient was the only patient in our cohort who lacked an HLA-identical sibling or a matched unrelated donor and therefore received a haploidentical, T cell-depleted allo-HSCT from his mother. Because of this, the patient was more intensively conditioned (TBI, etoposide, CY and muromonab CD3/OKT-3), which might explain the donor-derived endothelialisation (which probably resulted from more severe conditioning-related endothelial injury than in the other patients).
Our results are consistent with a study by Mueller et al., 44 who examined the level of endothelial cell chimaerism after allo-HSCT to delineate the role of haematopoietic stem cells in endothelial replacement.
Taken together, our results indicate that new vessel formation in the BM and VEGF expression are increased in patients with aGVHD and decline after aGVHD resolves, whereas no significant angiogenic activity is observable in the BM during cGVHD. In most of our patients, neovascularization was due to host-type endothelial cells. However, the relative contribution of donor-type neovascularisation and host-type neovascularisation during aGVHD remains to be studied in more detail. Whether neovascularisation reflects a secondary reaction in response to inflammation or a directly GVHD-related process is currently unknown. Murine models and our in situ results indicate that VE-cadherin might be a targetable molecule with respect to neoangiogenesis in aGVHD.
